Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
Clinical trial NCT07443488 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07443488
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-14
- Primary completion
- 2027-10-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.